Asset profile
ADX-629 · Aldeyra (ALDX)
- Indication
- alcohol-associated hepatitis
- Also known as
- ADX-629
Company
ALDXAldeyra
ALDXAldeyraAldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05392192 | Phase 2 | Completed | Apr 13, 2023 | 51 | 14 of 14 sites in the United States |
| NCT05717920 | Phase 2 | Completed | Nov 21, 2023 | 8 | 1 of 1 sites in the United States |
| NCT05487404 | Phase 1/2 | Completed | May 29, 2022 | 26 | 1 of 1 sites in the United States |
| NCT05443685 | Phase 1/2 | Completed | Apr 1, 2026 | 8 | 1 of 1 sites in the United States |
| NCT06685692 | Phase 2 | Completed | Jun 18, 2025 | 4 | 6 of 6 sites in the United States |
| NCT05599815 | Phase 2 | Withdrawn | May 1, 2023 | 0 | 11 of 11 sites in the United States |
| NCT04908514 | Phase 2 | Completed | Jan 21, 2022 | 10 | 1 of 1 sites in the United States |
| NCT04847544 | Phase 2 | Completed | Oct 15, 2021 | 11 | 1 of 1 sites in the United States |
| NCT04728711 | Phase 2 | Completed | Jan 18, 2022 | 8 | 0 of 1 sites in the United States |
More from Aldeyra
Other drugs and candidates from the same company tracked in this sector.